Nasdaq: TYRA
Developing Next-Generation Precision Molecules.
A clinical-stage biotechnology company advancing FGFR-focused precision medicines through the proprietary SNÅP Discovery Engine — capturing structural snapshots in as little as 7 days and refining molecular design to within a tenth of an angstrom.
Explore our approachScience
Our Approach
See the SNÅP Discovery Engine and the structural snapshots behind our molecular precision.
Learn moreInvestors
For Investors
Financials, SEC filings, webcasts, and events on our investor relations portal.
Learn morePatients
For Patients
Plain-language information about our programs and clinical studies.
Learn moreInvestigational; not approved by the FDA or any health authority.